US Edition
In race with Merus, Bicara makes the case for two-year survival data
Summary by Endpoints News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Endpoints NewsReposted by 
endpoints.news
endpoints.newsIn race with Merus, Bicara makes the case for two-year survival data
CHICAGO — Forced to play defense after its stock price fell 40% last month on competing data, Bicara hopes to win back some favor with new results for its head and neck cancer drug. In the ...
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
